글로벌 시상하부 비만 치료 시장 – 2023-2030

Overview
Global hypothalamic obesity treatment market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing at a CAGR of XX% during the forecast period 2023-2030.
Hypothalamic obesity (HO) is a type of obesity that is caused when the hypothalamus doesn’t function normally. Hypothalamic obesity is a complicated medical condition. It can happen from the growth of rare brain tumors. It can also happen from other types of injury to the hypothalamus. Craniopharyngioma is one of the tumors that can cause HyOb. Any injury to the hypothalamus can cause the condition. Genetic disorders affecting hypothalamic function can also lead to hypothalamic obesity.
Appropriate pituitary hormonal replacement, plus nutritional, physical activity, sleep and psychosocial interventions are important components of the management of hypothalamic obesity. For some individuals, medications such as anti-obesity drugs may be appropriate for weight management or bariatric surgery may also be an option. There are currently no approved drugs for the treatment of hypothalamic obesity, but drug interventions that tackle both the reduction of hyperphagia and the stimulation of thermogenesis are promising.
Market Dynamics: Drivers
Increasing demand for novel therapeutics
The increasing demand for novel therapeutics is expected to drive the market over the forecast period. The novel therapeutics aim to address the unmet needs associated with the management of hypothalamic obesity by providing alternative or complementary treatment options for better disease management.
The available treatment options for hypothalamic obesity were limited. If there is a growing understanding of the condition and an acknowledgment that existing treatments are not sufficient, it could drive the demand for new and improved therapeutic interventions. Moreover, many clinical trials are going on for the development of novel therapeutics that show better results in hypothalamic obesity treatment.
For instance, on November 02, 2022, Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, announced positive Phase 2 results and long-term extension trial data in hypothalamic obesity.
In addition, Rhythm announced the design of its Phase 3 clinical trial in acquired hypothalamic obesity, following recent discussions with the U.S. Food & Drug Administration (FDA). As announced, the FDA granted Breakthrough Therapy designation to setmelanotide for the treatment of hypothalamic obesity.
Scientific advancements and a deeper understanding of the underlying mechanisms of hypothalamic obesity may lead to the identification of new therapeutic targets. This, coupled with advancements in technology and drug development, could contribute to the development of novel treatments. The prevalence of hypothalamic obesity is on the rise, either due to increased awareness, better diagnostics or other factors, there would be an increased need for effective treatments. This, in turn, could drive the demand for novel therapeutics.
Further, the increasing prevalence of hypothalamic obesity, increasing clinical trials for better therapeutics and better management of the condition, increasing awareness about the condition and its severity and increasing advancements in the development of novel drugs and therapies are the factors expected to drive the market over the forecast period.
Restraints
Factors such as complications associated with the various medications, limited awareness about the condition, availability of alternative treatment options, lack of specific treatment and regulatory challenges are the factors expected to hamper the market.
Segment Analysis
The global hypothalamic obesity treatment market is segmented based on treatment type, end-user and region.
The anti-obesity drugs segment accounted for approximately 56.7% of the hypothalamic obesity treatment market share
The anti-obesity drugs segment is expected to hold the largest market share over the forecast period. Usually, there is no Food and Drug Administration (FDA) approved therapies for hypothalamic obesity. Anti-obesity drugs such as oxytocin, oral phentermine and topiramate, exenatide, tesofensine and setmelanotide for hypothalamic obesity have been increasingly used to promote further weight loss.
Phentermine is an appetite suppressant that affects the central nervous system to reduce appetite. Orlistat is a lipase inhibitor that decreases the absorption of dietary fat in the intestines. Liraglutide was originally developed for diabetes management, it also helps with weight loss by affecting appetite regulation. Bupropion and naltrexone combination medications, when combined, can help control appetite and cravings. Topiramate and phentermine combination may help with weight loss by affecting appetite and increasing feelings of fullness.
For instance, on June 19, 2023, Rhythm Pharmaceuticals presented six-month data showing a reduction in weight and body mass index (BMI) from the long-term extension of the Phase II trial of Imcivree (setmelanotide) in patients with hypothalamic obesity. Imcivree helps stimulate the melanocortin-4 receptor (MC4R) pathway to reduce hunger and promote weight loss.
Geographical Analysis
North America accounted for approximately 41.5% of the market share
North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and increasing prevalence in the region. North America especially the United States is known for its strong presence of major players such as pharmaceutical companies. The presence of major players is known to actively perform in clinical trials, which helps to the launch of novel therapeutics and alternative treatment options.
Furthermore, the increasing prevalence of hypothalamic obesity in the region is also expected to drive the market in the region. The increasing prevalence of the condition leads to increasing demand for hypothalamic obesity treatment options in the region, which leads to market dominance.
For instance, according to Rhythm medical research, in the United States, there is a 5000 to 10, 000 cases and more than 500 cases are increasing annually. In this prevalence, 2500 to 7500 cases are related to craniopharyngioma, more than 1000 cases are related to astrocytoma and more than 1500 cases related to other types of tumors.
Competitive Landscape
The major global players in the hypothalamic obesity treatment market include Rhythm Pharmaceuticals, Inc., LG Chem Life Sciences, Saniona, VIVUS LLC, Currax Pharmaceuticals LLC, Novo Nordisk Inc., Haleon Group and Eli Lilly and Company among others.
COVID-19 Impact Analysis
The COVID-19 pandemic significantly impacted the global hypothalamic obesity treatment market. During the pandemic, ongoing research activities including clinical trials for hypothalamic obesity are temporarily disrupted. Delays in research timelines could affect the development and introduction of new treatments. The pandemic also disrupted the supply chain of these therapeutics globally.
Market Segmentation
By Treatment Type
• Anti-Obesity Drugs
• Pituitary Hormonal Replacement
• Physical Activity
• Bariatric Surgery
• Others
By End-User
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Academic and Research Institutes
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Why Purchase the Report?
• To visualize the global hypothalamic obesity treatment market segmentation based on treatment type, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of hypothalamic obesity treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global hypothalamic obesity treatment market report would provide approximately 61 tables, 61 figures, and 187 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies